Double Bond Pharmaceutical International AB — Investor Relations & Filings

Double Bond Pharmaceutical International AB is a pharmaceutical company that focuses on redeveloping established drugs into new formulations to improve safety and efficacy. The company's core strategy involves changing the route of administration and utilizing proprietary drug delivery technologies. Its main technology platform, BeloGal®, is a biomimetic encapsulation system designed for targeted drug delivery to specific organs, aiming to increase therapeutic effects while reducing systemic toxicity. The development pipeline is focused on treatments for high-need areas, including cancer and infectious diseases. Key candidates in the pipeline include SI-053, a locally administered temozolomide gel for glioblastoma; SA-033, a targeted doxorubicin formulation for liver cancer; and Belopenem, which directs the antibiotic meropenem to the lungs to treat pneumonia.